JP7628962B2 - 乾癬性関節炎に罹患している対象者の治療方法 - Google Patents

乾癬性関節炎に罹患している対象者の治療方法 Download PDF

Info

Publication number
JP7628962B2
JP7628962B2 JP2021561000A JP2021561000A JP7628962B2 JP 7628962 B2 JP7628962 B2 JP 7628962B2 JP 2021561000 A JP2021561000 A JP 2021561000A JP 2021561000 A JP2021561000 A JP 2021561000A JP 7628962 B2 JP7628962 B2 JP 7628962B2
Authority
JP
Japan
Prior art keywords
antibody
week
composition
weeks
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021561000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529266A (ja
JPWO2020212874A5 (enExample
Inventor
ガノーカー，キルチ・ウォーダマン
ラウト，アトゥール・マチュラダス
ラガヴァン，アニール
ヤオ，シウ－ロン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2022529266A publication Critical patent/JP2022529266A/ja
Publication of JPWO2020212874A5 publication Critical patent/JPWO2020212874A5/ja
Priority to JP2025013906A priority Critical patent/JP2025069284A/ja
Application granted granted Critical
Publication of JP7628962B2 publication Critical patent/JP7628962B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021561000A 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法 Active JP7628962B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025013906A JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201921015050 2019-04-15
IN201921015050 2019-04-15
IN202021004422 2020-01-31
IN202021004422 2020-01-31
PCT/IB2020/053565 WO2020212874A1 (en) 2019-04-15 2020-04-15 Methods for treatment of subjects with psoriatic arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025013906A Division JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Publications (3)

Publication Number Publication Date
JP2022529266A JP2022529266A (ja) 2022-06-20
JPWO2020212874A5 JPWO2020212874A5 (enExample) 2023-04-20
JP7628962B2 true JP7628962B2 (ja) 2025-02-12

Family

ID=72837755

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021561000A Active JP7628962B2 (ja) 2019-04-15 2020-04-15 乾癬性関節炎に罹患している対象者の治療方法
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025013906A Pending JP2025069284A (ja) 2019-04-15 2025-01-30 乾癬性関節炎に罹患している対象者の治療方法

Country Status (16)

Country Link
US (1) US20220298233A1 (enExample)
EP (1) EP3956357A4 (enExample)
JP (2) JP7628962B2 (enExample)
KR (1) KR20210140780A (enExample)
CN (1) CN113825768A (enExample)
AU (1) AU2020259375A1 (enExample)
BR (1) BR112021020612A2 (enExample)
CA (1) CA3143604A1 (enExample)
IL (1) IL287213A (enExample)
JO (1) JOP20210279A1 (enExample)
MA (1) MA55729A (enExample)
MX (1) MX2021012652A (enExample)
MY (1) MY210310A (enExample)
PH (1) PH12021552536A1 (enExample)
SG (1) SG11202111056YA (enExample)
WO (1) WO2020212874A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202521154A (zh) * 2023-08-11 2025-06-01 大陸商信達生物製藥（蘇州）有限公司 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗ＩＬ２３ｐ１９抗體治療斑塊狀銀屑病的方法
WO2025051249A1 (zh) * 2023-09-07 2025-03-13 信达生物制药(苏州)有限公司 一种重组抗IL-23p19抗体治疗中重度银屑病的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807389B2 (en) * 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
BRPI0807710B1 (pt) * 2007-02-23 2021-12-14 Merck Sharp & Dohme Corp Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
PT2635601T (pt) * 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEODHAR, A. et al.，Lancet，2018年，Vol. 391，pp. 2213-2224
MEASE, P.J. et al.，Ann Rheum Dis ，2018年，Vol. 77, Suppl. 2, OP0307欄，doi: https://doi.org/10.1136/annrheumdis-2018-eular.2140

Also Published As

Publication number Publication date
BR112021020612A2 (pt) 2021-12-28
MX2021012652A (es) 2022-01-24
CN113825768A (zh) 2021-12-21
KR20210140780A (ko) 2021-11-23
MY210310A (en) 2025-09-10
PH12021552536A1 (en) 2022-07-04
MA55729A (fr) 2022-02-23
JP2025069284A (ja) 2025-04-30
US20220298233A1 (en) 2022-09-22
JP2022529266A (ja) 2022-06-20
CA3143604A1 (en) 2020-10-22
EP3956357A4 (en) 2023-01-04
EP3956357A1 (en) 2022-02-23
SG11202111056YA (en) 2021-11-29
WO2020212874A1 (en) 2020-10-22
JOP20210279A1 (ar) 2023-01-30
IL287213A (en) 2021-12-01
AU2020259375A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
JP2025069284A (ja) 乾癬性関節炎に罹患している対象者の治療方法
US20250066466A1 (en) Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
CN112689512B (zh) 用于治疗银屑病的组合物和方法
JP2025503948A (ja) 頭皮の尋常性乾癬を有する対象者の治療方法
US20220356261A1 (en) Treatment for sjögren's syndrome
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
US12497449B2 (en) Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
US20250263476A1 (en) Dosage regimens for treating multifocal motor neuropathy (mmn)
US20210179702A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
AU2023270497A1 (en) Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
US20240182598A1 (en) Compositions and methods for treating pediatric myasthenia gravis
WO2025146509A1 (en) Methods of treating multifocal motor neuropathy (mmn)
WO2024129468A1 (en) Methods for the treatment of noninfectious uveitis
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
JP2025534316A (ja) 非活動性又は慢性甲状腺眼症を処置するための方法
WO2025214333A1 (zh) 抗tslp抗体治疗与tslp相关的炎症疾病的方法
US20190247503A1 (en) Methods for treating relapsing forms of multiple sclerosis
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230412

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250130

R150 Certificate of patent or registration of utility model

Ref document number: 7628962

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150